Skip to main content

Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that data from its SANRECO Phase 2 study of divesiran, a first-in-class siRNA silencing TMPRSS6, in polycythemia vera (PV) was accepted for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting being held December 12-15, 2026 in New Orleans, LA.

Presentation Details:

Presenting Author: Marina Kremyanskaya MD PhD (Icahn School of Medicine at Mount Sinai)

Title: Sanreco phase 2 randomized, double-blind trial of divesiran in patients with polycythemia vera

Publication Number: 928

Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Molecular Insights and New Approaches in MPNs
Session Date: December 14, 2026
Presentation Time: 3:30 PM-3:45 PM CT
Room: Ernest N. Morial Convention Center (MCCNO) - Hall B

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.

Contacts

Inquiries:

Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
+1 (646) 637-3208
ir@silence-therapeutics.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.89
+0.00 (0.00%)
AAPL  351.91
+0.00 (0.00%)
AMD  503.41
+0.00 (0.00%)
BAC  49.44
+0.00 (0.00%)
GOOG  277.60
+0.00 (0.00%)
META  618.87
+0.00 (0.00%)
MSFT  506.24
+0.00 (0.00%)
NVDA  155.46
+0.00 (0.00%)
ORCL  115.00
+0.00 (0.00%)
TSLA  380.11
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.